In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hookipa Pharma Inc.

www.hookipabiotech.com

Latest From Hookipa Pharma Inc.

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Hookipa Biotech AG
  • Hookipa Biotech GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Hookipa Pharma Inc.
  • Senior Management
  • Joern Aldag, PhD, CEO
    Reinhard Kandera, CFO
    Daniel Pinschewer, PhD, CSO
    Igor Matushansky, MD, PhD, CMO & Global Head, R&D
    Christine Baker, CBO
  • Contact Info
  • Hookipa Pharma Inc.
    Phone: 1 890 63 60
    Helmut-Qualtinger-Gasse 2
    Vienna, 1030
    Austria
UsernamePublicRestriction

Register